30,978 Shares in 10x Genomics $TXG Purchased by Fox Run Management L.L.C.

Key Points

• Fox Run Management L.L.C. has acquired 30,978 shares of 10x Genomics ($TXG), valued at approximately $270,000, as part of its new position established in the first quarter.
• A significant number of hedge funds have also increased their stakes in 10x Genomics, with 84.68% of the stock currently held by institutional investors.
• 10x Genomics has recently reported a quarterly EPS of $0.28, surpassing consensus estimates by a significant margin, with revenues of $172.91 million compared to expectations of $139.36 million.

Fox Run Management L.L.C. purchased a new stake in shares of 10x Genomics (NASDAQ:TXG - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 30,978 shares of the company's stock, valued at approximately $270,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. ARK Investment Management LLC raised its position in shares of 10x Genomics by 7.5% during the 1st quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company's stock valued at $112,143,000 after purchasing an additional 901,656 shares during the period. Vanguard Group Inc. boosted its holdings in 10x Genomics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 11,118,086 shares of the company's stock worth $97,061,000 after buying an additional 184,537 shares during the period. RA Capital Management L.P. purchased a new stake in 10x Genomics in the 4th quarter worth $47,092,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of 10x Genomics by 10.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,116,573 shares of the company's stock valued at $30,394,000 after acquiring an additional 193,588 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its position in shares of 10x Genomics by 12.1% in the fourth quarter. Voloridge Investment Management LLC now owns 1,585,965 shares of the company's stock valued at $22,774,000 after acquiring an additional 171,161 shares in the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TXG has been the subject of several research analyst reports. Barclays reiterated an "overweight" rating and set a $15.00 target price (up previously from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. JPMorgan Chase & Co. cut their price objective on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a research report on Thursday, August 14th. Stephens reissued an "overweight" rating and issued a $14.00 target price on shares of 10x Genomics in a report on Thursday, May 15th. Finally, Morgan Stanley cut their target price on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Tuesday, August 12th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, 10x Genomics has an average rating of "Hold" and a consensus price target of $13.54.

10x Genomics Stock Performance

TXG stock traded down $0.23 during trading on Monday, hitting $14.07. 1,648,401 shares of the company's stock traded hands, compared to its average volume of 3,406,161. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $24.76. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -20.10 and a beta of 2.03. The business has a fifty day simple moving average of $12.65 and a 200 day simple moving average of $10.62.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm had revenue of $172.91 million for the quarter, compared to analysts' expectations of $139.36 million. During the same period in the prior year, the company earned ($0.32) EPS. The business's revenue was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. Research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.